Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017407 · ClinicalTrials.gov registry record · Phase 3
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00017407: Completed Phase 3 study, sponsored by Ionis Pharmaceuticals.
NCT00017407 is a Phase 3 study that has completed, run by Ionis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017407, a Phase 3 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without ISIS 3521. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel with or without ISIS 3521 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL ISIS 3521
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10-13 |
| Est. Completion | 2002-09-09 |
| Phase | Phase 3 |
What the finished NCT00017407 record still lists
NCT00017407 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00017407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00017407 about?
NCT00017407 is a clinical study titled "Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy. It is not yet known if carboplatin and paclitaxel are more effective with or without...
What is the current status of trial NCT00017407?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-10-13. Estimated completion is 2002-09-09.
What interventions are being tested in trial NCT00017407?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), ISIS 3521 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017407?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI